New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
12:39 EDTBAX, HALOFDA panel says HyQvia has favorable benefit-risk ratio, Bloomberg reports
The panel voted 15-1 that the drug from Baxter (BAX) and Halozyme (HALO) has a favorable risk/benefit in treatment of primary immune deficiency disorders, according to Bloomberg.
News For BAX;HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
09:02 EDTBAXBaxter presents IGSC 20% Phase 2,3 study
Subscribe for More Information
October 27, 2014
07:23 EDTBAXAmerican College of Surgeons holds a conference
Subscribe for More Information
07:22 EDTBAXAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 24, 2014
09:02 EDTBAXBaxter says FDA approves Obizur for acquired hemophilia A
Subscribe for More Information
October 21, 2014
06:29 EDTBAXBaxter management to meet with Leerink
Subscribe for More Information
October 20, 2014
12:36 EDTHALOOptions with decreasing implied volatility
Subscribe for More Information
09:04 EDTBAX, HALOBaxter, Halozyme launch HYQVIA in U.S.
Subscribe for More Information
08:32 EDTHALOHalozyme receives FDA approval for new Hylenex recombinant facilities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use